ClinicalTrials.gg
RecruitingNCT07441200Updated Oct 28, 2026

Clinical Trial of NS-863 in Participants With Pulmonary Arterial Hypertension (PAH)

A Phase 2 interventional study of NS-863 Low Dose and NS-863 High Dose in Pulmonary Arterial Hypertension, sponsored by NS Pharma, Inc.. Recruiting at 1 site in Japan. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-10-28.

Sponsored by NS Pharma, Inc. · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Sep 2026; still recruiting 1 month later.
Updated Oct 28, 2026Now RecruitingFirst site in Japan+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
135
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 41 studies in Pulmonary Arterial Hypertension with a site in Japan — 5 open to participants now, 9 under way, 5 of them phase 3. Pulmonary Arterial Hypertension · Japan.

Planned enrollment
18th of 37
135 · median 130
Started
2026
with 2 others
Phase 2
10 of 41
2 open now
Registered
39th of 41
by date

Among the 41 studies in Pulmonary Arterial Hypertension with a site in Japan, this one is the 18th largest by planned enrollment of the 37 interventional ones that give a count, is one of 3 that started in 2026, is one of 10 in phase 2, and was the 39th registered.

Pulmonary Arterial Hypertension

701 studies on the registry are indexed under Pulmonary Arterial Hypertension; 141 are open to participants now.

Browse Pulmonary Arterial Hypertension studies →

Open to participants now

5 of the 41 studies in Pulmonary Arterial Hypertension with a site in Japan are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in Japan have not opened yet or have stopped. Only those recruiting at a site in Japan →

Who these studies take

Of the 90 Pulmonary Arterial Hypertension studies recruiting now, 51 (57%) set no upper age limit and 24 (27%) stop at 75 or younger; 18 take children under 18; 11 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 41 studies in Pulmonary Arterial Hypertension with a site in Japan, or all of them as a file.
02

Study summary

A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Finding Trial to Evaluate the Efficacy and Safety of Orally Administered NS-863 in Participants with Pulmonary Arterial Hypertension (PAH)

03

Conditions studied

  • Pulmonary Arterial Hypertension

Keywords

  • Pulmonary Arterial Hypertension
04

Who can participate

The criteria were revised on the registry on Oct 28, 2026. See what changed

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Ability to provide written prior to participation in the trial, which includes the ability to comply with the requirements and restrictions listed in the informed consent form (ICF). Participants must be able to read, comprehend, and write at a level sufficient to complete trial-related materials
  • Adult male or female participants 18 (19 years in South Korea) to 75 years of age at the time the ICF is signed
  • Diagnosed with Group 1 PAH and pre-capillary PH defined by RHC during or at any time prior to the Screening Visit in any of the following subtypes:

    1. Idiopathic PAH (IPAH)
    2. Heritable PAH (HPAH)
    3. PAH associated drug and toxins (DPAH)
    4. PAH associated with connective tissue disease (PAH-CTD)
    5. PAH associated with congenital heart disease (PAH-CHD); simple systemic to pulmonary shunt at least 6 months after surgical repair
  • Diagnosed as WHO FC II, III, or IV on stable background therapy
  • Results of the RHC within 35 days prior to Day 1 and meet all of the following criteria:

    1. Participants receiving treatment with endothelin receptor antagonists, phosphodiesterase type 5 inhibitors, soluble guanylate cyclase stimulators, prostacyclin analogs or prostacyclin receptor agonists, calcium channel blocker, and/or diuretics are eligible only if on a stable dose for at least 90 days prior to RHC at baseline and throughout the Screening Period. For infusion prostacyclin analogs, dose adjustment based on the participant's body weight is allowed per medical practice. Stable diuretic therapy is defined as no addition of a new diuretic and no switching of a preexistent oral diuretic to parenteral administration; however, dose adjustments (up or down) in preexistent oral diuretics are acceptable
    2. Participants receiving treatment with activin-signaling inhibitor are eligible only if on a stable dose for at least 180 days prior to RHC at baseline and throughout the Screening Period. Dose adjustment based on the participant's body weight is allowed per medical practice.
  • Valid 6-minute walk distance (6MWD)
  • Women of (WOCBP) must have a negative pregnancy test before receiving the trial treatment and must agree to use from the Screening Visit to at least 30 days after the last dose of the trial treatment. Male participants who could potentially cause pregnancy must agree to use contraception from the Screening Visit to at least 90 days after the last dose of the trial treatment to avoid pregnancy in their partners
  • Able to complete the scheduled visits and follow the instructions of the investigator

Exclusion criteria

Exclusion Criteria:

  • Current diagnosis of the following PAH Group 1 subtypes:

    1. PAH associated with (HIV) infection
    2. PAH associated with portal hypertension
    3. PAH associated with schistosomiasis
    4. PAH with features of venous/capillary involvement
    5. Eisenmenger syndrome and PAH associated with prevalent systemic to pulmonary shunts in PAH-CHD
  • Have ≥3 of the following LV disease/dysfunction risk factors. :

    1. (BMI) ≥30 kg/m2 at the Screening Visit
    2. History of essential hypertension
    3. Diabetes mellitus (any type)
    4. Historical evidence of significant coronary artery disease
  • Diagnosis of PH Groups 2, 3, 4, or 5 of the classification
  • Moderate or severe obstructive lung disease ( [FEV1]/forced vital capacity [FVC] \<0.6) or restrictive lung disease (total lung capacity [TLC] \<70% of predicted value or lung diffusion capacity for carbon monoxide [DLco] \<45% except for PAH-systemic sclerosis) during the Screening Period.
  • Moderate or severe liver, renal, blood, or psychiatric disease:

    1. Moderate and severe hepatic impairment by the scoring system (Class B and Class C)
    2. Moderate and severe renal impairment by estimated (eGFR) \<60 mL/min/1.73 m2
    3. Have mental disorders or other conditions that make it difficult to follow the protocol
  • History of (per investigator's judgment) drug or alcohol abuse disorder
  • History of calculus urinary
  • History of acute kidney injury within 12 weeks prior to the start of the Screening Visit
  • Participants who have hematuria (>5 RBC/hpf) or proteinuria (urine albumin creatinine ratio [UACR] >150 mg/g or urine protein creatinine ratio [UPCR] >400 mg/g) at the Screening Visit
  • Initiation of pulmonary or cardiac rehabilitation within 12 weeks prior to baseline
  • Have diseases or symptoms that limit evaluation of 6MWT
  • is less than 1 year
  • Participants who are pregnant, breastfeeding, or planning to become pregnant during the time of trial participation
  • Severe acute or chronic medical or laboratory abnormality that may increase the risk associated with trial participation or trial treatment administration
  • Have a history of allergies to the in the trial treatment
  • Known HIV positive status
  • Active hepatitis due to virus or virus
  • Use of any protocol prohibited medications
  • Receipt of any within 4 weeks prior to the first dose of trial treatment or expected need for live vaccination during trial participation, including at least 4 weeks after the last dose of trial treatment
  • The investigator has judged the participant as unwilling or unable to comply with the protocol
  • Other concurrent disease and/or medical condition that, in the judgment of the investigator, may put the participant at risk or may influence the results of the trial or the participant's ability to complete the entire duration of the trial.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
135 participants (estimated)

Study arms

  • Active comparator
    NS-863 Low Dose

    NS-863 is an orally administered drug

    Drug: NS-863 Low Dose

  • Active comparator
    NS-863 High Dose

    NS-863 is an orally administered drug

    Drug: NS-863 High Dose

  • Placebo comparator
    NS-863 Placebo

    An orally administered NS-863 matching placebo

    Drug: NS-863 Placebo

Interventions

  • DrugNS-863 Low Dose

    NS-863 is an orally administered drug

  • DrugNS-863 High Dose

    NS-863 is an orally administered drug

  • DrugNS-863 Placebo

    An orally administered NS-863 matching placebo

06

What researchers measure

Primary outcomes

  1. Change in pulmonary vascular resistance (PVR) at week 24

    PVR is a hemodynamic variable of pulmonary circulation measured by right heart catheterization (RHC).

    Time frame: From baseline to week 24

  2. Number of participants who experienced an adverse event (AE) up to approximately 24 weeks.

    An AE is any untoward medical occurrence in a study participant administered a study drug, which did not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of the study drug. whether or not it was considered related to the study drug.

    Time frame: From baseline to week 24

Secondary outcomes

  1. Change in hemodynamic parameters at Week 24

    The hemodynamic parameters include mean right atrium pressure, mean pulmonary arterial pressure, systolic pulmonary artery pressure, diastolic pulmonary arterial pressure, cardiac output, pulmonary artery wedge pressure, stroke volume, and mixed venous oxygen saturation. The hemodynamic parameters will be used to calculate PVR, cardiac index, PVR index, total peripheral resistance, stroke volume index, and pulmonary artery compliance.

    Time frame: From baseline to week 24

  2. Change in 6-minute walk distance (6MWD) at weeks 12 and 24

    The 6MWD is the distance walked in 6 minutes as a measure of functional capacity. This will be assessed using the 6-minute walk test (6MWT).

    Time frame: From baseline to weeks 12 and 24

  3. Change in Borg dyspnea scale at Week 12 and 24

    Borg dyspnea scale is a measure used to assess an individual's exertion level during physical activity after the 6MWT

    Time frame: From baseline to weeks 12 and 24

  4. Change in Word Health Organization Functional Classification (WHO FC) at weeks 12 and 24

    The WHO FC describes the severity of symptoms and limitations in physical activity according to the following classes: * Class I: No symptoms and no limitation in ordinary physical activity. * Class II: Mild symptoms and slight limitation during ordinary activity. * Class III: Marked limitation in activity due to symptoms, even during less-than-ordinary activity. * Class IV: Severe symptoms experienced at rest, with inability to carry out any physical activity without discomfort

    Time frame: From baseline to weeks 12 and 24

  5. Change in echocardiogram at weeks 12 and 24

    An echocardiogram (echo) is a noninvasive, radiation-free ultrasound test that uses sound waves to produce moving images of the heart's structure, valves, and blood flow.

    Time frame: From baseline to weeks 12 and 24

  6. Change in PAH-Symptoms and Impact (SYMPACT®) at weeks 12 and 24

    The PAH-SYMPACT® is a self-rating questionnaire that measures the severity of PAH symptoms and their impact on daily life. The questionnaire consists of 16 symptoms and 25 impact items.

    Time frame: From baseline to weeks 12 and 24

07

Study locations

1 of 1 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2026 (actual). Primary completion is estimated for Aug 2028, 22 months after the start.

Of 28 industry-sponsored phase 2 interventional studies under Pulmonary Arterial Hypertension, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 48. This study's planned 22 months is below that.

Counting every sponsor, half of 52 studies reached it within 44 months; a quarter within 26 and three quarters within 65.

Start moved once since we started tracking on Sep 25, 2026: Jul 2026 → Sep 2026, on Oct 28, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jan 30, 2026
First posted
Feb 27, 2026
StartActual
Sep 29, 2026was Jul 2026
Primary completionEst.
Aug 1, 2028
CompletionEst.
Nov 1, 2028
Last update
Oct 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 28, 2026
Sites
1 site added — first site in Japan
Show site
  • Hospital of the University of Occupational and Environmental Health · Kitakyushu, Japan
Oct 28, 2026
Start date
Jul 1, 2026→Sep 29, 2026 (actual)
Oct 28, 2026
Eligibility
1 inclusion criterion edited; 2 exclusion criteria edited, 2 added
What changed in the criteria
Inclusion criteria
  • EditedAdult male or female participants 18 (19 years in South Korea) to 75 years of age at the time the ICF is signed
Exclusion criteria
  • EditedModerate and severe renal impairment by estimated glomerular filtration rate (eGFR) <60 mL/min/1.73 m2
  • AddedHistory of acute kidney injury within 12 weeks prior to the start of the Screening Visit
  • AddedParticipants who have hematuria (>5 RBC/hpf) or proteinuria (urine albumin creatinine ratio [UACR] >150 mg/g or urine protein creatinine ratio [UPCR] >400 mg/g) at the Screening Visit
  • EditedInitiation of pulmonary or cardiac rehabilitation within 12 weeks prior to baseline
Oct 28, 2026
Show all 1 update
  1. Oct 28, 2026
    Not yet recruiting→Recruiting
    1 site added — first site in Japan
    Show site
    • Hospital of the University of Occupational and Environmental Health · Kitakyushu, Japan
    Start date Jul 1, 2026→Sep 29, 2026 (now actual)
    Eligibility 1 inclusion criterion edited; 2 exclusion criteria edited, 2 added
    What changed in the criteria
    Inclusion criteria
    • EditedAdult male or female participants 18 (19 years in South Korea) to 75 years of age at the time the ICF is signed
    Exclusion criteria
    • EditedModerate and severe renal impairment by estimated glomerular filtration rate (eGFR) <60 mL/min/1.73 m2
    • AddedHistory of acute kidney injury within 12 weeks prior to the start of the Screening Visit
    • AddedParticipants who have hematuria (>5 RBC/hpf) or proteinuria (urine albumin creatinine ratio [UACR] >150 mg/g or urine protein creatinine ratio [UPCR] >400 mg/g) at the Screening Visit
    • EditedInitiation of pulmonary or cardiac rehabilitation within 12 weeks prior to baseline
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07441200
Lead sponsor
NS Pharma, Inc.
Collaborators
Nippon Shinyaku Co., Ltd.
Responsible party
Sponsor
First posted
Feb 27, 2026
Start date
Sep 29, 2026
Primary completion
Aug 1, 2028 (estimated)
Completion
Nov 1, 2028 (estimated)
Last update
Oct 28, 2026

Study contacts

Trial info
Contact
trialinfo@nspharma.com
1-866-677-4276

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion